Skip to content Norwegian Medical Products Agency Norwegian Medical Products Agency

Previous FINOSE-assessments

Published:

Changes

Page contents

    There has been finalized 5 FINOSE- assessments:

    Tecentriq - June 2019

    Assessment report for Tecentriq - June 2019 (pdf)

    Full indication in combination with bevacizumab, paclitaxel and carboplatin 
    Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies. 

    Assessed subgroups:

    • Patients with EGFR mutant or ALK-positive NSCLC after failure of appropriate targeted therapies
    • Patients with liver metastasis

    Xtandi - June 2019

    Assessment report for Ztandi - June 2019 (pdf)

    Assessed indication: Enzalutamide for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer

    Zynteglo - June 2020

    Assessment report for Zynteglo - June 2020 (pdf)

    Assessed indication: Zynteglo for the treatment of patients 12 years and older with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available

    FINOSE assessment used for joint procurement (SE/FI/NO/DK/IS) 

    Libmeldy - February 2022

    Assessment report for Libmeldy - February 2022 (pdf)

    Assessed indication: Libmeldy is indicated for the treatment of metachromatic leukodystrophy (MLD) characterized by biallelic mutations in the arylsulfatase A (ARSA) gene leading to a reduction of the ARSA enzymatic activity:

    • in children with late infantile or early juvenile forms, without clinical manifestations of the disease,
    • in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline

    Voxzogo - September 2023

    Assessment report for Voxzogo - September 2023 (pdf)

    Assessed indication: Voxzogo is indicated for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

    Contact us

    Area of expertise: HTA and reimbursement

    22 89 77 00

    FINOSE@noma.no